胃がん診断：市場洞察・競合環境・市場予測 (～2030年)

胃がん診断の市場規模は、2024年から2030年までの予測期間中にCAGR 7.31%で成長すると予測されています。

胃がん診断の需要は、主に世界中で胃がん患者が増加していることが背景にあります。ピロリ菌や胃腸炎などの胃感染症の増加と、GERDやその他の胃関連疾患の有病率の増加が市場の成長に寄与しています。さらに、胃がんの発症につながる肥満や喫煙習慣の増加も予測期間中の市場成長を促進する主な要因の一部です。

世界保健機関 (WHO) が国際がん研究機関 (IARC) と共同で実施した調査 (2022年) によると、胃がんの新規患者数は2020年の109万人から、2040年には181万人に増加し、新規患者数の75％がアジアで診断されると予測されています。この予測は、新規症例が約63％増加し、死亡率が66％増加することを示しています。同じ情報源によると、2020年には、消化器がんが世界のがん患者の4人に1人を占めると推計されています。

IARCの2024年のデータによると 、欧州の胃がんの総患者数は2022年の13万6,000人から、2045年には17万人に増加すると予想されています。

NCI (米国立がん研究所) が2024年1月に発表した研究によると、ヘリコバクターピロリ (ピロリ菌) は胃がんに関連する唯一の細菌性発がん物質であることが確認されています。2020年には、ピロリ菌は特に胃腫瘍という形で85万件の新たながん症例の原因となっていました。これらんことから、ピロリ菌感染の有病率の増加が胃がん診断市場の成長を牽引しています。

また、WHOは2024年、18歳以上の成人25億人が太りすぎであり、そのうち8億9,000万人が肥満であると報告しました。体重過多は血液中のインスリンや関連ホルモンの濃度を高め、胃がん発症のリスクを高めます。したがって、肥満者の増加も胃がん診断市場の拡大に寄与しています。

当レポートでは、世界の胃がん診断の市場を調査し、市場概要、市場影響因子および市場機会の分析、法規制環境、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 胃がん診断市場：イントロダクション

第2章 胃がん診断市場：エグゼクティブサマリー

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 胃がん診断市場：主要要因分析

• 市場促進要因
  • 世界中で胃がんの症例が増加
  • 胃食道逆流症（GERD）やその他の胃関連疾患の罹患率の増加
  • ピロリ菌や胃腸炎などの胃の感染症の増加
• 市場抑制要因と課題
  • 胃がん検診における偽陰性の可能性
  • 胃がんを早期発見するための診断ツールの非効率性
• 市場機会
  • 早期診断のための特異的バイオマーカーの発見
  • 胃がんの早期診断におけるAIとロボットの統合

第6章 胃がん診断市場：ポーターのファイブフォース分析

第7章 胃がん診断市場：市場評価

• 製品タイプ別
  • 機器
  • 試薬・キット
• 検査タイプ別
  • 画像検査
  • 臨床検査
• エンドユーザー別
  • 病院
  • 診断ラボ
  • 学術&研究機関
  • 診断センター
  • その他
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 胃がん診断市場：企業および製品プロファイル

• Abbott
• BD
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• Pillar Biosciences Inc.
• Hologic, Inc.
• CD Genomics
• Natera, Inc.
• Biodesix
• Illumina, Inc.
• Quest Diagnostics
• Agilent Technologies, Inc.
• FUJIFILM Holdings Corporation
• NeoGenomics Laboratories
• Guardant Health
• Myriad Genetics, Inc.
• Invitae Corporation
• Danaher

第9章 KOLの見解

第10章 プロジェクトアプローチ

第11章 DelveInsightについて

第12章 免責事項・お問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Gastric Cancer Diagnostics Market in Global (2021-2030)
• Table 3: Gastric Cancer Diagnostics Market in Global by Product Type (2021-2030)
• Table 4: Gastric Cancer Diagnostics Market in Global by Test Type (2021-2030)
• Table 5: Gastric Cancer Diagnostics Market in Global by End-User (2021-2030)
• Table 6: Gastric Cancer Diagnostics Market in Global by Geography (2021-2030)
• Table 7: Gastric Cancer Diagnostics Market in North America (2021-2030)
• Table 8: Gastric Cancer Diagnostics Market in the US (2021-2030)
• Table 9: Gastric Cancer Diagnostics Market in Canada (2021-2030)
• Table 10: Gastric Cancer Diagnostics Market in Mexico (2021-2030)
• Table 11: Gastric Cancer Diagnostics Market in Europe (2021-2030)
• Table 12: Gastric Cancer Diagnostics Market in France (2021-2030)
• Table 13: Gastric Cancer Diagnostics Market in Germany (2021-2030)
• Table 14: Gastric Cancer Diagnostics Market in the United Kingdom (2021-2030)
• Table 15: Gastric Cancer Diagnostics Market in Italy (2021-2030)
• Table 16: Gastric Cancer Diagnostics Market in Spain (2021-2030)
• Table 17: Gastric Cancer Diagnostics Market in the Rest of Europe (2021-2030)
• Table 18: Gastric Cancer Diagnostics Market in Asia-Pacific (2021-2030)
• Table 19: Gastric Cancer Diagnostics Market in China (2021-2030)
• Table 20: Gastric Cancer Diagnostics Market in Japan (2021-2030)
• Table 21: Gastric Cancer Diagnostics Market in India (2021-2030)
• Table 22: Gastric Cancer Diagnostics Market in Australia (2021-2030)
• Table 23: Gastric Cancer Diagnostics Market in South Korea (2021-2030)
• Table 24: Gastric Cancer Diagnostics Market in Rest of Asia-Pacific (2021-2030)
• Table 25: Gastric Cancer Diagnostics Market in the Rest of the World (2021-2030)
• Table 26: Gastric Cancer Diagnostics Market in the Middle East (2021-2030)
• Table 27: Gastric Cancer Diagnostics Market in Africa (2021-2030)
• Table 28: Gastric Cancer Diagnostics Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Gastric Cancer Diagnostics Market in Global (2021-2030)
• Figure 3: Gastric Cancer Diagnostics Market in Global by Product Type (2021-2030)
• Figure 4: Gastric Cancer Diagnostics Market in Global by Test Type (2021-2030)
• Figure 5: Gastric Cancer Diagnostics Market in Global by End-User (2021-2030)
• Figure 6: Gastric Cancer Diagnostics Market in Global by Geography (2021-2030)
• Figure 7: Gastric Cancer Diagnostics Market in North America (2021-2030)
• Figure 8: Gastric Cancer Diagnostics Market in the United States (2021-2030)
• Figure 9: Gastric Cancer Diagnostics Market in Canada (2021-2030)
• Figure 10: Gastric Cancer Diagnostics Market in Mexico (2021-2030)
• Figure 11: Gastric Cancer Diagnostics Market in Europe (2021-2030)
• Figure 12: Gastric Cancer Diagnostics Market in France (2021-2030)
• Figure 13: Gastric Cancer Diagnostics Market in Germany (2021-2030)
• Figure 14: Gastric Cancer Diagnostics Market in United Kingdom (2021-2030)
• Figure 15: Gastric Cancer Diagnostics Market in Italy (2021-2030)
• Figure 16: Gastric Cancer Diagnostics Market in Spain (2021-2030)
• Figure 17: Gastric Cancer Diagnostics Market in the Rest of Europe (2021-2030)
• Figure 18: Gastric Cancer Diagnostics Market in Asia-Pacific (2021-2030)
• Figure 19: Gastric Cancer Diagnostics Market in China (2021-2030)
• Figure 20: Gastric Cancer Diagnostics Market in Japan (2021-2030)
• Figure 21: Gastric Cancer Diagnostics Market in India (2021-2030)
• Figure 22: Gastric Cancer Diagnostics Market in Australia (2021-2030)
• Figure 23: Gastric Cancer Diagnostics Market in South Korea (2021-2030)
• Figure 24: Gastric Cancer Diagnostics Market in Rest of Asia-Pacific (2021-2030)
• Figure 25: Gastric Cancer Diagnostics Market in the Rest of the World (2021-2030)
• Figure 26: Gastric Cancer Diagnostics Market in the Middle East (2021-2030)
• Figure 27: Gastric Cancer Diagnostics Market in Africa (2021-2030)
• Figure 28: Gastric Cancer Diagnostics Market in South America (2021-2030)
• Figure 29: Market Drivers
• Figure 30: Market Barriers
• Figure 31: Marker Opportunities
• Figure 32: PORTER'S Five Force Analysis

Gastric Cancer Diagnostics Market by Product Type (Instruments, Reagents & Kits), Test Type (Imaging Test [Upper Endoscopy, Barium Swallow/X-Rays, CT Scan, Laparoscopy, MRI, Stomach Ultrasound, and Others], Laboratory Test [Biopsy, Blood Test, and Others]), End-Users (Hospitals, Diagnostic Laboratories, Academic & Research Institutes, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing to the growing prevalence of gastric cancer, increasing cases of stomach infection such as h. pylori and gastroenteritis, among others

The gastric cancer diagnostics market is estimated to grow at a CAGR of 7.31% during the forecast period from 2024 to 2030. The demand for gastric cancer diagnostics is primarily being driven by the rising cases of gastric cancer across the globe. The growing prevalence of GERD and other stomach-related conditions coupled with increasing cases of stomach infections such as H. Pylori and gastroenteritis is contributing to the growth of the market. Further, the rising obesity and smoking habits leading to the development of stomach cancer are some of the key factors that are driving the market growth of the gastric cancer diagnostics market during the forecast period from 2024 to 2030.

Gastric Cancer Diagnostics Market Dynamics:

According to the study conducted by the World Health Organization (WHO) in collaboration with the International Agency for Research on Cancer (IARC) (2022), WHO projects gastric cancer incidence to increase from 1.09 million new cases in 2020 to 1.81 million by 2040, with 75 percent of new cases diagnosed in Asia. This trajectory indicates an upsurge of around 63% in new cases and a corresponding 66% rise in mortality rates, due to a lack of diagnosis and treatment facilities in poor countries. According to the same source in 2020, Gastrointestinal (GI) cancers accounted for 1 in 4 cancer cases in the world.

According to the International Agency for Research on Cancer (IARC) (2024), the total number of stomach cancer cases was 136 thousand in 2022 and this number is expected to reach 170 thousand by 2045 in Europe.

A study published by the National Cancer Institute in January 2024 highlighted that Helicobacter pylori (H. pylori) is the only confirmed bacterial carcinogen linked to gastric cancer. In 2020, H. pylori was responsible for 850,000 new cancer cases, particularly in the form of gastric tumors. Consequently, the increasing prevalence of H. pylori infections is driving the growth of the gastric cancer diagnostics market.

Additionally, the World Health Organization (WHO) reported in 2024 that 2.5 billion adults aged 18 years or older were overweight in 2022, with 890 million of them living with obesity. Excess body weight leads to higher levels of insulin and related hormones in the blood, which in turn increases the risk of developing stomach cancer. Therefore, the rising number of obese individuals is also contributing to the expansion of the gastric cancer diagnostics market.

However, the chances of false-negative results in gastric cancer screening and, the inefficiency of diagnostic tools to detect gastric cancer at an early stage, among others are some of the key constraints that may hinder the growth of the gastric cancer diagnostics market.

Gastric Cancer Diagnostics Market Segment Analysis:

Gastric Cancer Diagnostics Market By Product Type (Instruments, Reagents & Kits), Test Type (Imaging Test [Upper Endoscopy, Barium Swallow/X-Rays, CT Scan, Laparoscopy, MRI, Stomach Ultrasound, and Others], Laboratory Test [Biopsy, Blood Test, and Others]), End-Users (Hospitals, Diagnostic Laboratories, Academic & Research Institutes, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the gastric cancer diagnostics market, the reagents & kits category was estimated to generate a significant revenue share in the gastric cancer diagnostics market in 2023. This can be attributed to the growing use of reagents and kits in cancer diagnosis due to the rising prevalence of gastric cancer across the globe. The growing awareness about early cancer diagnosis is a major factor contributing to the growth of the segment. In gastric biopsy, essential reagents encompass fixatives like formalin for tissue preservation, staining agents such as hematoxylin and eosin for microscopic analysis, and immunohistochemical stains aiding in the identification of cancer cell markers. Additionally, common markers utilized for gastric cancer detection include Carcinoembryonic antigen (CEA) and Carbohydrate antigen 19-9 (CA 19-9), with mucin-staining reagents being frequently employed in diagnostic procedures. These reagents are widely used in procedures for early gastric cancer diagnosis.

In October 2021, Boditech Med Inc. launched the ichroma Tumor triple-M diagnostic kit. This product is specifically developed for the early detection of gastric cancer. It contains Carcinoembryonic Antigen (CEA), a vital component utilized in the identification of stomach cancer. CEA serves as a pivotal tool in cancer screening, monitoring, prognostics, and predictive analysis both pre and post-surgery.

Further, the utilization of reagents and kits for the examination and detection of proteins and genes in gastric cancer diagnosis, particularly for early detection and facilitating appropriate treatment, significantly fuels the expansion of this segment. Therefore, the growing use of reagents and kits is expected to contribute to the growth of the segment, thereby driving the growth of the overall gastric cancer diagnostics market during the forecast period.

North America Is Expected To Dominate The Overall Gastric Cancer Diagnostics Market:

North America was estimated to account for the largest market share in the gastric cancer diagnostics market in 2023. This is due to the rising prevalence of gastric cancer and other stomach diseases contributing to the growth of gastric cancer. Additionally, the rising geriatric population and technological advancement in early cancer diagnosis are the major factors contributing to the growth of the gastric cancer diagnostics market in the region.

According to data published by the American Cancer Society in January 2024, approximately 26,890 new cases of stomach cancer are projected to occur in the United States in 2024. Of these, men are estimated to account for 16,160 cases, while women will account for 10,730 cases. Stomach cancer represents about 1.5% of all new cancer diagnoses in the country each year. This type of cancer predominantly affects older individuals, with the average age of diagnosis being 68 years, and around 60% of cases occurring in those aged 65 and older. The lifetime risk of developing stomach cancer is significantly higher in men, with approximately 1 in 101 men and 1 in 155 women facing this risk.

The Population Reference Bureau (2024) forecasts a substantial increase in the demographic of Americans aged 65 and above, from 58 million in 2022 to 82 million by 2050, representing a 47% surge. The proportion of the total population in this age group is expected to rise from 17% to 23%. Gastric cancer is more prevalent among older individuals due to several aging-related risk factors such as stomach infections and gastroesophageal reflux disease (GERD). Consequently, the growing geriatric population is expected to drive the expansion of the gastric cancer diagnostics market in the region.

In March 2024, Ibex Medical Analytics introduced Galen, an AI-powered cancer diagnostic platform. Galen provides accurate diagnoses, reduces manual operations, and is utilized for diagnosing gastric cancer, H. pylori, and other gastric lesions such as adenoma and low-grade dysplasia. Therefore, increasing R&D activities by key players to develop advanced diagnostic solutions is anticipated to foster growth in the North American gastric cancer diagnostics market.

Gastric Cancer Diagnostics Market Key Players:

Some of the key market players operating in the gastric cancer diagnostics market include Abbott, BD, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Pillar Biosciences Inc., Hologic, Inc., CD Genomics, Natera, Inc., Biodesix, Illumina, Inc., Quest Diagnostics, Agilent Technologies, Inc., FUJIFILM Holdings Corporation, NeoGenomics Laboratories, Guardant Health, Myriad Genetics, Inc., Invitae Corporation, Danaher, and others.

Recent Developmental Activities In The Gastric Cancer Diagnostics Market:

• In March 2024, AI Medical Service Inc. announced that it had launched gastroAI-model G, an AI-based endoscopic diagnostic support device that operates within the stomach. The diagnostic device operates by scanning for potential lesions, utilizing images derived from the video processor of the endoscopy system. Upon determining that a lesion appears suspicious for early gastric cancer and requires additional evaluation, the program notifies the physician and offers diagnostic support by presenting a highlighted area within the endoscopic display.
• In November 2023, Dedalus Group in collaboration with Ibex Medical Analytics, announced the launch of a fully integrated AI-powered digital pathology solution for gastric cancer diagnosis.
• In August 2023, Mirxes Pte Ltd, announced today that its flagship product GASTROClear, a PCR-based in vitro diagnostic test for early detection of gastric (stomach) cancer, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). It is a molecular blood test for the early detection of gastric cancer that helps to cure cancer with affordable treatment.

Key Takeaways From The Gastric Cancer Diagnostics Market Report Study

• Market size analysis for current Gastric Cancer Diagnostics Market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
• Key companies dominating the Gastric Cancer Diagnostics market.
• Various opportunities available for the other competitors in the Gastric Cancer Diagnostics Market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current Gastric Cancer Diagnostics market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Gastric Cancer Diagnostics market growth in the coming future?

Target Audience Who Can Be Benefited From This Gastric Cancer Diagnostics Market Report Study

• Gastric Cancer Diagnostics product providers
• Research organizations and consulting companies
• Gastric Cancer Diagnostics-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Gastric Cancer Diagnostics
• Various end-users who want to know more about the Gastric Cancer Diagnostics Market and the latest technological developments in the Gastric Cancer Diagnostics Market.

Frequently Asked Questions For The Gastric Cancer Diagnostics Market:

1. What are Gastric Cancer Diagnostics?

Gastric cancer diagnostics refers to the set of procedures and technologies utilized to identify and assess the presence of gastric (stomach) cancer in individuals suspected of harboring the disease. These methods encompass a spectrum of diagnostic tools, including imaging modalities, laboratory assays, endoscopic evaluations, and histopathological examinations of tissue samples obtained via biopsies.

2. What is the market for Gastric Cancer Diagnostics?

The gastric cancer diagnostics market is estimated to grow at a CAGR of 7.31% during the forecast period from 2024 to 2030.

3. What are the drivers for the Gastric Cancer Diagnostics market?

The demand for gastric cancer diagnostics is primarily being driven by the rising cases of gastric cancer across the globe. The growing prevalence of GERD and other stomach-related conditions coupled with increasing cases of stomach infections such as H. Pylori and gastroenteritis is contributing to the growth of the market. Further, the rising obesity and smoking habits leading to the development of stomach cancer are some of the key factors that are driving the market growth of the gastric cancer diagnostics market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the Gastric Cancer Diagnostics market?

Some of the key market players operating in the gastric cancer diagnostics market include Abbott, BD, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Pillar Biosciences Inc., Hologic, Inc., CD Genomics, Natera, Inc., Biodesix, Illumina, Inc., Quest Diagnostics, Agilent Technologies, Inc., FUJIFILM Holdings Corporation, NeoGenomics Laboratories, Guardant Health, Myriad Genetics, Inc., Invitae Corporation, Danaher, and others.

5. Which region has the highest share in the Gastric Cancer Diagnostics market?

North America was estimated to account for the largest market share in the gastric cancer diagnostics market in 2023. This is due to the rising prevalence of gastric cancer and other stomach diseases contributing to the growth of gastric cancer. Additionally, the rising geriatric population and technological advancement in early cancer diagnosis are the major factors contributing to the growth of the gastric cancer diagnostics market in the region.

Table of Contents

1. Gastric Cancer Diagnostics Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Gastric Cancer Diagnostics Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Gastric Cancer Diagnostics Market Key Factors Analysis

• 5.1. Gastric Cancer Diagnostics Market Drivers
  • 5.1.1. The rising cases of gastric cancer across the globe
  • 5.1.2. Growing prevalence of GERD and other stomach-related conditions
  • 5.1.3. Increasing cases of stomach infections such as H. Pylori and gastroenteritis
• 5.2. Gastric Cancer Diagnostics Market Restraints and Challenges
  • 5.2.1. Chances of false negative results in gastric cancer screening
  • 5.2.2. The inefficiency of diagnostic tools to detect gastric cancer at an early stage
• 5.3. Gastric Cancer Diagnostics Market Opportunity
  • 5.3.1. Discovery of specific biomarkers for early diagnosis
  • 5.3.2. Integration of AI and robotics in early gastric cancer diagnostics

6. Gastric Cancer Diagnostics Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Gastric Cancer Diagnostics Market Assessment

• 7.1. By Product Type
  • 7.1.1. Instruments
  • 7.1.2. Reagents & Kits
• 7.2. By Test Type
  • 7.2.1. Imaging Test
    • 7.2.1.1. Upper Endoscopy
    • 7.2.1.2. Barium Swallow/X-Rays
    • 7.2.1.3. CT Scan
    • 7.2.1.4. Laparoscopy
    • 7.2.1.5. MRI
    • 7.2.1.6. Stomach Ultrasound
    • 7.2.1.7. Others
  • 7.2.2. Laboratory Test
    • 7.2.2.1. Biopsy
    • 7.2.2.2. Blood Test
    • 7.2.2.3. Others
• 7.3. By End-User
  • 7.3.1. Hospitals
  • 7.3.2. Diagnostic Laboratories
  • 7.3.3. Academic & Research Institutes
  • 7.3.4. Diagnostic Centers
  • 7.3.5. Others
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
    • 7.4.1.2. Canada Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
    • 7.4.1.3. Mexico Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
  • 7.4.2. Europe
    • 7.4.2.1. France Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
    • 7.4.2.2. Germany Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
    • 7.4.2.3. United Kingdom Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
    • 7.4.2.4. Italy Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
    • 7.4.2.5. Spain Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
    • 7.4.2.6. Rest of Europe Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
    • 7.4.3.2. Japan Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
    • 7.4.3.3. India Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
    • 7.4.3.4. Australia Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
    • 7.4.3.5. South Korea Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
    • 7.4.3.6. Rest of Asia-Pacific Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
    • 7.4.4.2. Africa Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
    • 7.4.4.3. South America Gastric Cancer Diagnostics Market Size In USD Million (2021-2030)

8. Gastric Cancer Diagnostics Market Company and Product Profiles

• 8.1. Abbott
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. BD
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Bio-Rad Laboratories, Inc.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. F. Hoffmann-La Roche Ltd
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Siemens Healthineers AG
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Thermo Fisher Scientific Inc.
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Pillar Biosciences Inc.
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Hologic, Inc.
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. CD Genomics
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Natera, Inc.
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Biodesix
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Illumina, Inc.
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Quest Diagnostics
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Agilent Technologies, Inc.
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. FUJIFILM Holdings Corporation
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. NeoGenomics Laboratories
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Guardant Health
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Myriad Genetics, Inc.
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Invitae Corporation
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. Danaher
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us